PD 173955

Confirm delete?

PD 173955

Zoom

Cat No: 30618

Biochemicals - Kinase Inhibitors

PD 173955 is a tyrosine kinase inhibitor.{57211,20180} It inhibits c-Src, Yes, and LCK (IC50s = 25, 22, and 5 nM, respectively), as well as Bcr-Abl and c-Kit (IC50s = 1-2 and 25 nM, respectively), and is selective for these kinases over the insulin re...

This product can only be bought through Cayman Chemical. Please contact us.

Product Overview
Data
Downloads
About Cayman

Territorial Availability: Available through Bertin Technologies only in France

Synonyms:

6-(2,6-dichlorophenyl)-8-methyl-2-[[3-(methylthio)phenyl]amino]-pyrido[2,3-d]pyrimidin-7(8H)-one

Correlated keywords:

PD173955 cSrc BcrAbl cKit ?FGFR G 2 SKOV 3 HT29 A 549 431 MDAMB468 MB468 MDAMB MCF7

Product Overview:
PD 173955 is a tyrosine kinase inhibitor.{57211,20180} It inhibits c-Src, Yes, and LCK (IC50s = 25, 22, and 5 nM, respectively), as well as Bcr-Abl and c-Kit (IC50s = 1-2 and 25 nM, respectively), and is selective for these kinases over the insulin receptor (InsR), α-FGFR, basic FGFR (bFGFR), PDGFR, and PKC.{54239,57211,20180} PD 173955 (5,000 nM) induces cell cycle arrest at the G2/M phase in DU145 prostate, SKOV3 ovarian, HT-29 colon, A549 lung, and A431 skin cancer cells.{57211} It inhibits proliferation of MDA-MB-468 and MCF-7 breast cancer cells (IC50s = 500 and 1,000 nM, respectively), as well as patient-derived peripheral blood chronic myelogenous leukemia (CML) progenitor cells (IC50= ~7.5 nM).{57211,20180}

Size	1 mg
Shipping	dry ice
CAS Number	260415-63-2
Molecular Formula	C₂₁H₁₆Cl₂N₄OS
SMILES	CSC1=CC=CC(NC2=NC=C(C=C(C3=C(Cl)C=CC=C3Cl)C(N4C)=O)C4=N2)=C1
Molecular Weight	443,4
Formulation	A crystalline solid
Purity	≥98%
Custom Code	2930.90
UNSPSC code	12352100

Technical File

MSDS

Click here to ask for your quote and get 15% off Cayman's products.

Cayman Chemical's mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.

Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.

Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.

Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.

Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009

Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.